The role of MIRO2 in tumor cell invasion and metastasis

MIRO2在肿瘤细胞侵袭和转移中的作用

基本信息

  • 批准号:
    10464387
  • 负责人:
  • 金额:
    $ 3.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-04-01 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

Project Abstract/Summary Cancer is the second leading cause of death in the United States. Overall survival for patients with tumors that remain localized to the tissue of origin remain relatively high, while it is estimated that 90% of all cancer related deaths are due to metastatic dissemination to secondary sites. This underscores the importance of identifying signaling pathways that promote metastasis. Mitochondria are multifunctional organelles with important roles in regulating many cellular processes outside of ATP production and are recognized for their roles in tumorigenesis and metastasis. This project seeks to define a novel mechanism that promotes tumor cell invasion and metastasis through a previously unidentified signaling pathway between Mitochondrial Rho GTPase 2 (MIRO2) and atypical myosin IXB (MYO9B). MIRO2 is an outer-mitochondrial membrane protein that is a part of the MIRO subfamily of Ras GTPases. MIROs were first characterized in neurons where they are involved in the anterograde and retrograde trafficking of mitochondria. MIRO2 has been shown by several groups to be dispensable for mitochondrial trafficking in many non-neuronal cell types. Our lab has previously shown that MIRO2 mRNA is enriched in tumorigenic tissues in many tumor types when compared to normal tissue. Additionally, we have shown in prostate cancer that MIRO2 is important in tumor cell viability, anchorage-dependent and -independent growth, and tumor growth in vivo. Despite this initial evidence, it remains unknown if MIRO2 exclusively impacts the primary tumor or if this is also important in metastasis. My initial results show that loss of MIRO2 reduces the invasive capacity of tumor cells from many tumor types including breast, melanoma, pancreas, and prostate. Furthermore, I have shown out of the top newly identified MIRO2 binding partners, loss of MYO9B reduces invasive capacity to the greatest extent. MYO9B is known to control cell motility by localizing to the leading edge of migrating cells and inactivating RhoA through MYO9B’s Rho GTPase activating protein (GAP) domain. Excitingly, I show that loss of both MIRO2 and MYO9B result in increased active RhoA. Given this evidence, I hypothesize MIRO2 promotes tumor cell invasion and metastasis through positively regulating MYO9B GAP activity. In this proposal I will 1) determine the role of MIRO2 in tumor cell invasion and metastasis and 2) determine the mechanism in which MIRO2 regulates tumor cell invasion. This proposal will utilize many models including, but not limited to: 2D/3D in vitro invasion systems, live cell imaging of migrating cells, in vivo breast cancer metastasis models, cell-free GTPase assays, co-immunoprecipitation, and proximity ligation assays. Overall, the goal of this proposal is to serve as the basis for the development of novel therapeutics to target metastatic disease.
项目摘要/摘要 癌症是美国第二大死亡原因。肿瘤患者的总生存期 仍然局限于起源组织的癌症仍然相对较高,而据估计,90%的癌症 相关的死亡是由于转移到第二部位。这突出了以下方面的重要性: 识别促进转移的信号通路。线粒体是多功能的细胞器, 在调节ATP产生之外的许多细胞过程中起重要作用,并因其 在肿瘤发生和转移中的作用。该项目旨在确定一种新的机制,促进肿瘤细胞 线粒体Rho GT3与肿瘤侵袭转移的信号通路 2(MIRO 2)和非典型肌球蛋白IXB(MYO 9 B)。 MIRO 2是一种线粒体外膜蛋白,是Ras GTP酶MIRO亚家族的一部分。 MIRO首先在参与顺行和逆行运输的神经元中进行表征 of mitochondria线粒体. MIRO 2已经被几个研究小组证明是线粒体运输的关键。 许多非神经细胞类型。我们的实验室先前已经表明,MIRO 2 mRNA在致瘤性细胞中富集, 与正常组织相比,许多肿瘤类型的组织。另外,我们在前列腺癌中发现, MIRO 2在肿瘤细胞活力、锚定依赖性和非依赖性生长以及肿瘤生长中是重要的 in vivo.尽管有这一初步证据,但仍不清楚MIRO 2是否专门影响原发性肿瘤,或者是否 在转移中也很重要。我的初步结果表明,MIRO 2的丢失降低了肿瘤的侵袭能力, 来自许多肿瘤类型的细胞,包括乳腺癌、黑色素瘤、胰腺癌和前列腺癌。此外,我还展示了 在最新鉴定的MIRO 2结合配偶体中,MYO 9 B的缺失最大程度地降低了侵入能力 程度已知MYO 9 B通过定位于迁移细胞的前缘并使其失活来控制细胞运动性。 RhoA通过MYO 9 B的Rho GTP酶激活蛋白(GAP)结构域。令人兴奋的是,我表明,损失的两个MIRO 2 和MYO 9 B导致活性RhoA增加。鉴于这一证据,我假设MIRO 2促进肿瘤细胞 MYO 9 B GAP活性与肿瘤侵袭转移密切相关。 在这个提案中,我将1)确定MIRO 2在肿瘤细胞侵袭和转移中的作用,2) 确定MIRO 2调节肿瘤细胞侵袭的机制。该提案将利用许多模型 包括但不限于:2D/3D体外侵入系统、迁移细胞的活细胞成像、体内乳腺癌 癌症转移模型、无细胞GT3测定、免疫共沉淀和邻位连接测定。 总的来说,这项提案的目标是作为开发新疗法的基础, 转移性疾病

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dillon Boulton其他文献

Dillon Boulton的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dillon Boulton', 18)}}的其他基金

The role of MIRO2 in tumor cell invasion and metastasis
MIRO2在肿瘤细胞侵袭和转移中的作用
  • 批准号:
    10704512
  • 财政年份:
    2022
  • 资助金额:
    $ 3.62万
  • 项目类别:

相似国自然基金

益气活血法对4T1乳腺癌细胞肺转移及SDF-1/CXCR4生物轴的干预作用
  • 批准号:
    81503517
  • 批准年份:
    2015
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目
固本抑瘤Ⅱ号祛邪、扶正组分不同时期应用对4T1乳腺癌细胞生长转移及mTOR通路介导的自噬作用差异研究
  • 批准号:
    81202689
  • 批准年份:
    2012
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Differential proteome analysis identifies TGF-beta related pro-metastatic proteins in a 4T1 murine breast cancer model
差异蛋白质组分析鉴定 4T1 小鼠乳腺癌模型中的 TGF-β 相关促转移蛋白
  • 批准号:
    25871241
  • 财政年份:
    2013
  • 资助金额:
    $ 3.62万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了